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Aim To assess the relationship between Helicobacter pylori 
(H. pylori) infection and atrophic gastritis (AG) and intesti-
nal metaplasia (IM) development and to assess the rate of 
dysplasia or gastric cancer development in patients with 
AG and/or IM.
Methods This retrospective endoscopic follow-up study 
enrolled 2214 patients. The patients were followed for at 
least five years between 2007 and 2017 at the Department 
of Endoscopy at Antalya Ataturk Government Hospital. The 
results of third-year and five-year surveillance biopsy were 
assessed.
Results The mean follow-up time was 7.77 ± 2.78 years. H. 
pylori was histologically assessed in 1417 (64.6%) patients. 
Of 198 patients with severe H. pylori infection, 32 (16%) and 
139 (70.3%) developed extensive AG and extensive IM, re-
spectively. There was a significant relationship between H. 
pylori density and AG and IM degrees. High grade dyspla-
sia, early gastric cancer, and advanced gastric cancer were 
diagnosed in 73 patients with median age 58.2 (28-80) 
years, and the incidence rate was 3.29% (73/2214). The an-
nual incidence of gastric neoplastic lesions was 0.46% in 
total, 0.08% for early GC, and 0.02% for advanced gastric 
cancer.
Conclusions H. pylori infection has an important role in 
the development of AG and IM. H. pylori density is directly 
related to atrophy and metaplasia degree.
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Helicobacter pylori (H. pylori) is a widely spread bacterium 
causing atrophic gastritis (AG), intestinal metaplasia (IM), 
dysplasia, and eventually gastric cancer (1). Gastric cancer 
ranks fourth in terms of prevalence and second in terms 
of the number of cancer-related deaths. The most com-
mon gastric cancer type is intestinal type adenocarcinoma, 
which is closely associated with H. pylori infection (2).
In H. pylori-related AG, the glandular tissue in the stomach 
disappears, while in IM the surface foveolar and glandular 
epithelium of the gastric mucosa is replaced with intestinal 
epithelium. In general, metaplasia is the cell’s protective re-
sponse to changing ambient conditions, since sulfomucins 
and sialomucins in the intestinal mucosa are resistant to 
bacterial enzymes. AG and IM are considered the precur-
sors of gastric cancer (3-5). It is widely believed that they 
could be ameliorated by H. pylori eradication (6). H. pylori 
infection is a risk factor for developing gastric carcinoma 
(1). However, only a few infected patients develop gastric 
cancer, which is why it is important to identify the H. py-
lori gastritis characteristics that increase the risk for gastric 
carcinoma. We investigated whether a simple comparison 
of the gastritis grade and chronic inflammation in the an-
trum and corpus might help identify patients with H. pylori 
gastritis with an increased cancer risk. To answer this ques-
tion, we retrospectively assessed whether patients with AG 
and/or IM with H. pylori developed gastric cancer or dys-
plasia in at least 5-year follow up.
PATIENTS AND METHODS
In this endoscopic follow-up study, we retrospectively re-
viewed the charts of patients who underwent first gastros-
copy at the Department of Endoscopy at Antalya Ataturk 
Government Hospital. The gastroscopy was performed 
due to epigastric pain, abdominal bulge, nausea, vomit-
ing, and heartburn with at least one premalignant lesion 
in the stomach biopsy. The patients were followed up for 
more than 5 years between 2007 and 2017. The exclusion 
criteria included stomach adenocarcinoma, mucosal as-
sociated lymphoid tumor, gastrectomy, previous H. pylori 
eradication therapy, and age under 18 years. Baseline and 
surveillance endoscopies were performed by experienced 
gastroenterologists with Fujinon EG 450 WL5 (Fujifilm Eu-
rope GmbH, Dusseldorf, Germany) and Pentax EG-2980 K 
unit (Pentax Medical, Montvale, NJ, USA).
All patients underwent endoscopic examination of the 
esophagus, stomach, and duodenum. During the first en-
doscopy, two non-targeted antral and two gastric body bi-
opsies were performed by using Olympus biopsy forceps 
(Olympus Europa, Hamburg, Germany). All biopsy speci-
mens were fixed in 10% formalin and examined at the 
Pathology Department. H. pylori density was determined 
with Giemsa dye.
Histopathological classification was made according to 
the updated Sydney System (7) (Table 1). All biopsy sam-
ples were evaluated for H. pylori, IM, AG, and dysplasia and 
graded according to their density as absent, mild (grade 1), 
moderate (grade 2), and severe (grade 3). The dysplasia de-
gree was assessed using the Vienna system; dysplasia was 
graded as low-grade to high-grade or neoplasia. A con-
trol endoscopy was performed after 3 years, with biopsies 
performed and evaluated in the same manner as at base-
line. H. pylori infection was treated by triple (proton pump 
inhibitor, clarithromycin, and amoxicillin) and quadruple 
therapy (proton pump inhibitor, bismuth, metronidazole, 
and tetracyline). The patients underwent endoscopic ex-
amination after having given written and verbal consent. 
This study was approved by the institutional review board 
of the University of Health Sciences Antalya Training and 
Research Hospital (13.08.2020-12/10).
Statistical analysis
The Pearson and Kruskal-Wallis tests were used to evaluate 
the differences in outcome proportions (at least LGD or at 
least HGD) and to assess the differences in patients’ age, 
sex, Hp infection prevalence, and disease duration. Survival 
analysis was performed to define the rate of progression to 
outcome at the third- and fifth-year follow up endoscopy. 
Outcome was considered as progression to lesions as se-
vere as LGD. Age was presented with median, minimum, 
TABlE 1. Updated Sydney System (8)
Histologic properties Definition Mild Moderate Severe
Chronic inflammation Lymphocyte and plasma cell propria + ++ +++
Neutrophil activation Neutrophil infiltration in the lamia propria or superficial epithelium <l/3 1/3-2/3 >2/3
Glandular atrophy Loss of corpus and antral glands + ++ +++
Intestinal metaplasia Intestinal metaplasia in the mucosal epithelium <l/3 1/3-2/3 >2/3
Helicobacter pylori Helicobacter pylori intensity in the epithelium + ++ +++
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and maximum value. The level of significance was set at 
0.05. The analysis was conducted with SPSS, version 17.0 
(SPSS, Chicago, IL, USA).
RESUlTS
The study enrolled 2214 patients (1285 or 58.3% male). 
Men and women did not significantly differ in median age 
(54.5 [18-64] women and 58.5 [18-69] men, P = 0.495) (Ta-
ble 2). The mean follow-up period was 7.77 ± 2.78 years. H. 
pylori was histologically confirmed in 1417 (64.6%) of 2214 
patients.
H. pylori density was significantly associated with chronic in-
flammation degree (P = 0.001), atrophy degree (P = 0.0001), 
and IM degree (P = 0.0028). Significantly more patients 
with H. pylori had chronic inflammation, atrophy, and IM 
compared with patients without H. pylori (Table 3, Table 4, 
Table 5). A total of 493 patients with H. pylori infection si-
multaneously had histologic features of IM and AG.
IM was most frequently detected by follow-up endosco-
py. High grade dysplasia (HGD), early gastric adenocarci-
noma (early gastric cancer), and advanced gastric adeno-
carcinoma (advanced gastric cancer) were diagnosed in 73 
patients (24 women, median age 58.2 [49-68] years), with 
the crude incidence rate of 3.29% (Table 6). These patients 
were followed-up more closely. In 28 of the 73 gastric can-
cer patients, biopsy was taken from the suspicious areas 









<30 133 (55.2) 108 (44.8)  241
30-49 261 (36.7) 451 (63.3)  712
50-59 146 (26.5) 405 (73.5)  551
>60 257 (36.2) 453 (63.8)  710
Sex
female 393 (42.4) 536 (57.6)  929 (41.7)
male 404 (31.5) 881 (68.5) 1285 (58.3)
TABlE 3. The prevalence of chronic inflammation in patients with and without Helicobacter pylori infection
 No. (%) of patients
H. pylori-negative (N = 797) H. pylori-positive (N = 1417)
none mild (+) moderate (++) severe (+++) total
Chronic inflammation
mild 605 (75.9) 654 (81.3) 226 (55)  8 (4) 888 (62.6)
moderate 151 (18.9) 121 (15.5) 140 (33.9)  64 (32.3) 325 (22.9)
severe  41 (5.2)  32 (3.2)  46 (11.1) 126 (68.7) 204 (14.3)
total 797 807 (56.9) 412 (29) 198 (13.9) 1417
Odds ratio 3.8
95% confidence interval 3.47-4.2
P <0.01
TABlE 4. The prevalence of gastric atrophy in patients with and without Helicobacter pylori infection
No. (%) of patients
H. pylori-negative (N = 797) H. pylori-positive (N = 1417)
none mild (+) moderate (++) severe (+++) total
Gastric atrophy
none 713 (89.4) 582 (72) 256 (62)  86 (43)  924 (65.2)
mild  84 (10.5) 225 (28)   0   0  225 (15.8)
moderate   0   0 113 (27.6)  80 (41)  193 (13.6)
severe   0   0  43 (10.4)  32 (16)   75 (5.29)
total 797 807 (56.9) 412 (29) 198 (13.9) 1417
Odds ratio 3.3
95% confidence interval 3.13-3.47
P <0.01
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of IM or visible lesions. Biopsies from visible lesions were 
evaluated as high-grade advanced GC in 3 patients, as IM 
in 14 patients, as early GC in 4 patients, and as high-grade 
dysplasia in 6 patients.
Among 73 patients with neoplastic lesions, 57 patients had 
lesions localized in the antrum (35 low-grade dysplasia, 14 
high-grade dysplasia, 5 early GC, and 3 advanced GC). Six-
teen patients had lesions localized in the gastric body (9 
LGD, 4 HGD, and 3 early GC) (Table 7).
The annual incidence rate of total gastric neoplastic lesions 
per person was 0.46%. The annual incidence of LGD, HGD, 
early GC, and advanced GC was 0.37%, 0.18%, 0.08%, and 
0.02%, respectively.
A total of 364 patients had moderate and severe IM and/or 
moderate and severe AG. Severe metaplasia and atrophy 
at first biopsy progressed at a higher rate than others, both 
at 3 and 5 years after diagnosis.
TABlE 5. The prevalence of intestinal metaplasia in patients with and without Helicobacter pylori infection
No. (%) of patients
H. pylori-negative (N = 797) H. pylori-positive (N = 1417)
none mild (+) moderate (++) severe (+++) total
Intestinal metaplasia
none 713 (89.4) 583 (72)   0   0  583 (41.1)
mild  84 (10.5) 170 (21.4) 246 (59.7)   0  416 (29.3)
moderate   0  54 (6.6) 166 (40.3) 139 (70.3)  359 (25.3)
severe   0   0   0  59 (29.7)   59 (4.1)
total 797 807 (56.9) 412 (29) 198 (13.9) 1417
Odds ratio 5.6
95% confidence interval 5.12-5.96
P 0.0028
TABlE 6. Histological lesions found at outcome endoscopic biopsy at the first, third, and fifth year after diagnosis according the le-
sion found at entry biopsy, n (%)
Third-year biopsy Fifth-year biopsy
First biopsy lGD HGD EGC AGC lGD HGD EGC AGC
Atrophy
+ 225 24 (10.6) 1 (0.4) 0 0 29 (12.8)  4 (1.7) 0 0
++ 193 21(10.8) 3 (1.5) 0 0 32 (16.5) 12 (6.2) 0 0
+++  75  8(10.6) 2 (2.6) 0 0 11 (14.6)  6 (8) 0 2 (2.6)
Metaplasia
+ 416 21 (5) 4 (0.9) 0 0 32 (7.6) 14 (3.3) 0 0
++ 359 18 (5) 5 (1.3) 0 0 28 (7.7) 19 (5.2) 0 5 (1.3)
+++  59  4 (6.7) 2 (3.3) 0 0  7 (11.8)  9 (15.2) 0 2 (3.3)
*lGD – low grade dysplasia; HGD – high grade dysplasia; EGC – early gastric carcinoma; AGC – advanced gastric carcinoma.
TABlE 7. Characteristics of patients who developed gastric neoplastic lesions at follow-up
lGD HGD Early GC Advanced GC
Antrum 35 14 5 3
Corpus  9  4 3 -
Age 49 to 68 years, median age 58.2 ± 5.74 years
Gender 24 women, 49 men (P < 0.05)
Crude incidence rate 73/2214
Average length of follow-up 7.77 ± 2.78 year
*lGD – low grade dysplasia; HGD – high grade dysplasia; GC – gastric carcinoma.
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DISCUSSION
In this study, at baseline biopsy, all lesions (AG, IM, LGD) 
were equally prevalent. The patients with AG or IM at first 
biopsy did not develop cancer during the following three 
years, and less than 5% progressed to HGD. Although we 
did not confirm the direct effect of H. pylori infection on le-
sion progression, it is a potential risk factor for cancer, be-
cause it causes chronic gastritis and leads to atrophy. We 
found no significant differences in age, sex, H. pylori infec-
tion prevalence, and follow up duration according to the 
histological diagnosis of the first lesion.
Several studies have shown that the presence and severity 
of H. pylori infection correlates with chronic gastritis, AG, 
and IM (8). As is well known, AG and IM are important risk 
factors for gastric cancer, together with genetic and other 
environmental factors (9). In AG cases, the risk of gastric 
cancer development increases with disease duration, at-
rophy severity, IM presence, dysplasia, epigenetic changes, 
and H. pylori infection. In 10% of cases with AG, gastric can-
cer can develop within 10-20 years (10-12).
A 20-year prospective study by Lahner et al showed a per-
son-year incidence of gastric cancer in patients with AG to 
be 0.25% (4). Another study (13) observed 8.4% cases of 
gastric cancer among patients with IM and AG who were 
followed up for 10 years, with endoscopy being performed 
once a year. The risk of developing malignancy in these pa-
tients was 11% (13).
A Dutch nationwide cohort study found the annual gastric 
cancer incidence to be 0.1%, 0.25%, 0.6%, and 6% in 5 years 
in patients with AG, IM, mild, and moderate and severe 
dysplasia (14). East Asian countries have higher gastric ade-
nocarcinoma prevalence than Western countries (15), and 
the prevalence of H. pylori in Turkey is similar to Asian coun-
tries. Since patients with extensive IM have a high risk of 
gastric cancer, they are recommended to undergo follow-
up endoscopy (16-18). Similar to other studies, our study 
found extensive AG and/or IM to be risk factors for gastric 
cancer and dysplasia. As we have already noted, H. pylori in-
fection is an important etiological factor for gastric cancer, 
and its eradication reduces the risk of cancer development 
(19). Some authors have also reported that IM areas in the 
stomach after H. pylori treatment convert into normal mu-
cosa, meaning that the progression to gastric cancer can 
be prevented. However, complete prevention can only be 
achieved by H. pylori eradication therapy before AG and IM 
develop (20). Although chronic AG may be cured after bac-
terial eradication, AG and IM or dysplasia still present a high 
risk for progression to gastric cancer (21).
In the study by Kwak et al (22), most of 1833 gastric can-
cer patients had H. pylori infection. In our study, all of 73 
new patients with gastric cancer had intestinal adenocar-
cinoma and 55 of them had H. pylori with IM. This result 
shows a significant relationship between H. pylori and gas-
tric intestinal adenocarcinoma. In H. pylori carriers with all 
precancerous lesions, H. pylori eradication significantly re-
duced the development of gastric cancer (5). Our study 
also showed that more than half of patients with precan-
cerous lesions were H. pylori positive.
These data show that H. pylori infection plays an important 
role in the development of atrophy and IM. We also ob-
served that activity and atrophy increased with an increase 
in H. pylori density. Performing routine biopsies can contrib-
ute to H. pylori eradication and IM and AG treatment. How-
ever, it is very important to determine the most suitable 
screening intervals as early diagnosis can reduce the num-
ber of cancer deaths. European guidelines (23) recommend 
a screening interval of 3 years in patients with extensive AG 
and IM. A Korean study determined that the mean screen-
ing interval of 2.37 years was appropriate for gastric cancer 
detection (24). In a Japanese case-control study, patients 
who underwent 3-year endoscopic screening intervals had 
reduced gastric cancer-related mortality by 30% compared 
with non-screened patients (25). These studies show 2- or 
3-year intervals are not superior to each other (26). Con-
sistent with all these studies, we showed that endoscopic 
screening period of 3 years would be sufficient for early de-
tection of GC for patients with extensive AG and IM.
The study is limited by retrospective and single-center 
design. In addition, histological diagnosis of H. pylori was 
made only by Giemsa staining, and biopsy specimens were 
evaluated by a single pathologist. We also obtained only 
two biopsies from the gastric antrum and body, which is 
fewer than in other studies and may have prevented us 
from observing some small premalignant lesions. Due to 
the retrospective design, we were not able to assess pa-
tients’ smoking status, consumption of salted food and al-
cohol, and family history, which are all known risk factors 
for the development of GC. The use of white light endos-
copy can also be considered a limitation as new guidelines 
recommend the use of narrow band imaging for early de-
tection of premalignant gastric lesions (23). Target sam-
pling in uneven areas with narrow band imaging (NBI) 
increases the likelihood of finding a pathological le-
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sion and the reliability of the study. However, NBI endos-
copy is not commonly used in routine practice in Turkey. In 
addition, we did not assess the IM subtypes in accordance 
with recent studies, as it was not clinically significant.
In conclusion, patients with chronic gastritis with H. py-
lori, IM, and AG had an increased risk for gastric cancer. In 
these patients, screening endoscopy can detect early gas-
tric cancer. Further prospective, long-term, large-scale fol-
low up studies with immunohistochemical methods and 
double-blind assessment by two or three pathologists are 
necessary to assess gastric intestinal adenocarcinoma de-
velopment in H. pylori patients.
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